Effect of intrasphincteric botulinum toxin on postoperative urinary retention following stapled hemorrhoidopexy: a randomized, double-blind, placebo-controlled trial Authors: Mina Alvandipour, Sina Safari, Maryam Vahidpoor, Ava Ranjbar, Mehdi Karimi Published: 2026 ABSTRACT Postoperative urinary retention (POUR) is a frequent and clinically significant complication following stapled hemorrhoidopexy, often resulting in catheterization, prolonged hospitalization, and patient discomfort. Strategies to reduce POUR remain limited. Intrasphincteric botulinum toxin (BTX) injection may decrease internal anal sphincter tone and indirectly reduce urinary dysfunction. To evaluate the effect of intrasphincteric BTX type A injection on the incidence of POUR following stapled hemorrhoidopexy in a secondary analysis of a prospective randomized controlled trial originally designed to assess postoperative pain outcomes. In this double-blind, placebo-controlled trial, 68 adult patients with grade III–IV hemorrhoids undergoing stapled hemorrhoidopexy at two tertiary hospitals were randomized (1:1) to receive either 50 units of BTX A or placebo injected into the internal anal sphincter intraoperatively. The primary outcome was POUR, defined as failure to void within six hours postoperatively with a bladder volume > 400 mL on ultrasound requiring catheterization. Secondary outcomes included postoperative pain, gas incontinence, bleeding, and anal stenosis. POUR occurred in 30 patients (44.1%). The incidence was significantly lower in the BTX group compared with placebo (20.6% vs. 67.6%, P < 0.001). In multivariable logistic regression adjusted for age and sex, placebo treatment was independently associated with higher odds of POUR (adjusted OR 8.87, 95% CI 2.82–27.95; P < 0.001). No significant differences were observed in postoperative bleeding or gas incontinence. Intrasphincteric BTX injection significantly reduces postoperative urinary retention following stapled hemorrhoidopexy and may represent an effective perioperative strategy to improve surgical.Registration: IRCT20130826014483N12; Registered 25 June 2025 (Retrospectively registered).Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53489-1. Introduction Postoperative urinary retention (POUR) is a well recognized and clinically significant complication following anorectal surgery, particularly hemorrhoidectomy and stapled hemorrhoidopexy, with reported incidences ranging widely between 3% and 50% across diverse case series and observational cohorts1,2.POUR is defined as the inability to spontaneously void following surgery, often necessitating catheterization, prolonging hospital stay, and contributing to patient discomfort, infection risk, and additional healthcare resource utilization1,3. Although stapled hemorrhoidopexy was initially promoted for its benefits in reducing postoperative pain and accelerating recovery compared with traditional excisional techniques, POUR remains a common sequela even after this procedure4. The multifactorial pathophysiology of POUR after anorectal surgery includes autonomic neural reflex inhibition, pelvic floor guarding secondary to pain, bladder overdistension from spinal anesthesia, and the effects of perioperative opioids and intravenous fluids1,5. Pain induced reflex sympathetic activation and pelvic nerve irritation contribute to dysfunctional detrusor contraction and increased urethral sphincter tone, both of which can precipitate acute urinary retention5,6. Furthermore, spinal or epidural anesthesia, frequently employed in anorectal procedures, has been independently associated with higher rates of POUR due to transient blockade of the micturition reflex arc1,7. Beyond its prevalence, POUR is clinically meaningful due to its association with delayed mobilization, increased risk of urinary tract infection, and patient discomfort8,9. Traditional prevention strategies have focused on perioperative pain control, judicious fluid management, and minimizing the duration of neuraxial blockade, yet these approaches are inconsistently effective and often inadequate at fully preventing retention3,10. In the absence of targeted pharmacologic or procedural interventions, POUR continues to impose a substantive burden on postoperative care pathways and patient experience11,12. Interestingly, interventions aimed at reducing internal anal sphincter (IAS) hypertonia, such as intrasphincteric botulinum toxin (BTX) injection, have demonstrated promising effects on related perioperative outcomes. BTX has been studied primarily for its capacity to reduce sphincter spasm and postoperative pain by chemically inducing temporary relaxation of the IAS13,14. Although earlier randomized studies have focused on pain as the principal outcome, data from related clinical trials indicate that BTX may also influence the incidence of POUR, likely through a combination of reduced pelvic floor guarding and improved smooth muscle relaxation15. However, these findings have not been systematically leveraged to evaluate urinary retention as a clinical endpoint, leaving a gap in the perioperative literature regarding its potential role as a preventive measure for this complication. Given the frequent occurrence and clinical importance of POUR, and the biological plausibility that modulation of anal sphincter tone could impact urinary bladder function via contiguous pelvic neuromuscular pathways, a focused investigation of BTX’s effect on POUR following stapled hemorrhoidopexy is both timely and warranted. This investigation represents a secondary analysis of a previously conducted randomized controlled trial originally designed to evaluate postoperative pain outcomes. In this analysis, POUR is examined as a distinct secondary outcome. The study therefore aims to examine the independent effect of intrasphincteric BTX injection on the incidence of urinary retention, adjusted for demographic factors, and delineating its implications for perioperative management in anorectal surgery. Materials and methods Study design and participants This study represents a secondary analysis of a previously conducted prospective, randomized, double-blind, placebo-controlled trial, which was originally designed to assess postoperative pain outcomes following stapled hemorrhoidopexy. The current analysis focuses on the incidence of POUR as a secondary outcome. The study was conducted at Imam Khomeini and Shafa Hospitals (Sari, Iran) between January 2024 and December 2025, after obtaining approval from the Ethics Committee of Mazandaran University of Medical Sciences and written informed consent from all participants according to the Declaration of Helsinki. Sixty eight eligible adults aged 18 years or older, diagnosed with symptomatic grade III or IV hemorrhoids, and scheduled for stapled hemorrhoidopexy were enrolled. Exclusion criteria included inflammatory bowel disease, anorectal fistula or fissure, prior anorectal surgery, proctitis, pregnancy, severe cardiopulmonary disease, neurological conditions affecting bladder function, and urologic disorders predisposed to urinary retention. A CONSORT flow diagram is provided in Fig. 1. Fig. 1CONSORT flow diagram. CONSORT flow diagram. Randomization and blinding Patients were randomly assigned in a 1:1 ratio to receive either intrasphincteric BTX A or placebo injection during surgery. Randomization was achieved using a computer generated sequence, with concealed allocation through sealed opaque envelopes prepared by an independent researcher. Both patients and all clinical staff, including surgeons, anesthesiologists, and outcome assessors, were blinded to group assignment to ensure double blind conditions. Surgical procedure All stapled hemorrhoidopexy procedures were performed by a single experienced colorectal surgeon using a standard circular stapler technique (Covidien Autosuture). After completion of the stapled mucosal resection, patients in the intervention group received 50 units of botulinum toxin type A diluted in 2 mL of 0.9% saline injected into the internal anal sphincter at the anterior and posterior midline quadrants using a 23 gauge needle. The placebo group received an equal volume of saline at the same sites. Syringes were indistinguishable to maintain blinding. No anal packing was used in either group. Anesthesia protocol All patients underwent standardized spinal anesthesia according to institutional protocol. Hyperbaric bupivacaine 0.5% (12–15 mg, 2.4–3.0 mL) was administered intrathecally at the L3–L4 or L4–L5 interspace to achieve sensory block up to T10–T12 dermatomes. In selected cases, 15–25 µg fentanyl was added intrathecally as an adjuvant. Patients were monitored with continuous ECG, noninvasive blood pressure, and pulse oximetry throughout the operation. Sedation and perioperative management Minimal intravenous sedation was administered only when required for patient comfort, typically with a small dose of midazolam 1–2 mg given intravenously or a low dose continuous infusion of propofol at 25–50 micrograms per kilogram per minute, while maintaining spontaneous ventilation. All patients received standard prophylactic antibiotic therapy with ceftriaxone 1 gram intravenously, delivered within 30 to 60 min before the surgical incision. Postoperative care was identical in both groups and followed the routine institutional protocol. Postoperative analgesia Pain control followed a multimodal regimen routinely used in enhanced recovery protocols. Patients received acetaminophen (1,000 mg IV or oral every 6 h) and diclofenac sodium (75 mg intramuscular every 12 h) or alternatively ketorolac (30 mg IV every 8 h). For breakthrough pain, morphine 2–4 mg IV was administered incrementally to a maximum of 10–12 mg in the first 24 h. “Analgesic dose (mg)” was defined as the cumulative total NSAID (diclofenac equivalent) consumption during the first postoperative day. Outcome measures The primary outcome of this study was POUR. POUR was defined as failure to achieve spontaneous voiding within six hours after surgery, accompanied by symptoms of bladder fullness or discomfort, and confirmed by bladder ultrasound showing a post void bladder volume greater than 400 mL, requiring urethral catheterization. Bladder volume was assessed using a portable bladder scanner by trained clinical staff, and the decision to perform catheterization was made according to the institutional protocol when bladder volume exceeded the predefined threshold or when patients experienced significant discomfort. This definition was selected based on commonly used diagnostic criteria for postoperative urinary retention reported in previous surgical studies16,17. Secondary outcomes included postoperative pain intensity measured using the Visual Analogue Scale (VAS), gas incontinence, postoperative bleeding, and anal stenosis. Pain intensity was assessed on postoperative day 1, week 1, and week 2 using the VAS scale (0 = no pain, 10 = worst imaginable pain). Gas incontinence was evaluated based on patient self report during follow up visits, while postoperative bleeding and anal stenosis were recorded if observed during clinical assessment. Statistical analysis No formal sample size calculation was performed for POUR, as the original trial was powered for postoperative pain outcomes. Therefore, this secondary analysis may be underpowered to detect smaller differences in POUR incidence. This limitation is addressed in the Discussion. All analyses were performed using Stata version 19.5 (StataCorp LLC, College Station, Texas, USA). Continuous variables were reported as means ± standard deviations (SD) for normally distributed data or as medians with interquartile ranges (IQR) for non normally distributed variables. Categorical variables were expressed as frequencies and percentages. Group comparisons were conducted using the Student’s t-test or Mann–Whitney U test for continuous variables, and the chi square test or Fisher’s exact test for categorical variables, as appropriate. To evaluate factors associated with postoperative urinary retention, multivariable logistic regression analysis was performed adjusting for potential confounders including age and sex. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were reported. To explore whether the treatment effect differed between men and women, a treatment by sex interaction term was included in the regression model. Predicted probabilities of postoperative urinary retention were estimated using marginal effects derived from the adjusted model. Additionally, absolute risk reduction (ARR) and the number needed to treat (NNT) were calculated to quantify the clinical impact of BTX administration. A two sided P value < 0.05 was considered statistically significant. Follow-up Patients were followed at postoperative day 1, week 1, and week 2. During these visits, the primary outcome (postoperative urinary retention) and secondary outcomes (pain intensity, gas incontinence, bleeding, and anal stenosis) were assessed. Outcome assessment was performed by a blinded surgical resident who was unaware of the treatment allocation. Trial registration This randomized controlled trial was prospectively registered in the Iranian Registry of Clinical Trials (IRCT) under the registration number IRCT20130826014483N12. The study protocol was additionally submitted and verified in the Iranian Registry of Research (iRCR) with the identifier 84,312. Registration occurred prior to patient enrollment and adhered fully to CONSORT recommendations for trial transparency and public documentation. Results A total of 68 patients undergoing stapled hemorrhoidopexy were randomized equally to the BTX (n = 34) and placebo (n = 34) groups, and all patients completed the study protocol and were included in the final analysis (Fig. 1). Baseline demographic and clinical characteristics were well balanced between groups (Table 1). The mean age was 45.2 ± 11.4 years in the BTX group and 46.8 ± 10.9 years in the placebo group (P = 0.56), and the proportion of male patients was comparable (52.9% vs. 58.8%; P = 0.62). Distributions of hemorrhoid grade, operative time, intraoperative fluid volume, and history of predisposing conditions, constipation, or previous anal surgery were similar between groups (Table 1), confirming successful randomization. Table 1Baseline demographics and clinical characteristics of study participants.VariableBTX group (n = 34)Placebo group (n = 34)P-valueAge (years), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:45.2\pm\:11.4$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:46.8\pm\:10.9$$\end{document} 0.56Sex (male), n (%)18 (52.9%)20 (58.8%)0.62Hemorrhoid grade, n (%)0.78Grade III21 (61.8%)23 (67.6%)Grade IV13 (38.2%)11 (32.4%)Operative time (min), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:38.5\pm\:8.2$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:37.1\pm\:7.5$$\end{document} 0.46Intraoperative fluids (mL), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:1250\pm\:280$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:1280\pm\:310$$\end{document} 0.68Predisposing conditions, n (%)4 (11.8%)5 (14.7%)0.72Constipation history, n (%)14 (41.2%)15 (44.1%)0.81Previous anal surgery, n (%)3 (8.8%)2 (5.9%)0.64Values are presented as mean ± SD, median (IQR), or n (%). Predisposing conditions include benign prostatic hyperplasia, recurrent urinary tract infections, or previous pelvic surgery. Table 1Baseline demographics and clinical characteristics of study participants.VariableBTX group (n = 34)Placebo group (n = 34)P-valueAge (years), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:45.2\pm\:11.4$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:46.8\pm\:10.9$$\end{document} 0.56Sex (male), n (%)18 (52.9%)20 (58.8%)0.62Hemorrhoid grade, n (%)0.78Grade III21 (61.8%)23 (67.6%)Grade IV13 (38.2%)11 (32.4%)Operative time (min), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:38.5\pm\:8.2$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:37.1\pm\:7.5$$\end{document} 0.46Intraoperative fluids (mL), mean ± SD \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:1250\pm\:280$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:1280\pm\:310$$\end{document} 0.68Predisposing conditions, n (%)4 (11.8%)5 (14.7%)0.72Constipation history, n (%)14 (41.2%)15 (44.1%)0.81Previous anal surgery, n (%)3 (8.8%)2 (5.9%)0.64Values are presented as mean ± SD, median (IQR), or n (%). Predisposing conditions include benign prostatic hyperplasia, recurrent urinary tract infections, or previous pelvic surgery. Baseline demographics and clinical characteristics of study participants. Values are presented as mean ± SD, median (IQR), or n (%). Predisposing conditions include benign prostatic hyperplasia, recurrent urinary tract infections, or previous pelvic surgery. The primary outcome, POUR, occurred in 30 of 68 patients (44.1%). Incidence of POUR differed markedly between groups, with 7 of 34 patients (20.6%) in the BTX group and 23 of 34 patients (67.6%) in the placebo group experiencing retention (P < 0.001; Table 2). This corresponds to a relative risk reduction of 70% and a clinically meaningful absolute risk reduction, as depicted in Fig. 2. Table 2Incidence of postoperative urinary retention (POUR).Groupn/N%Relative Risk (95% CI)P-valueBTX7/3420.60.30 (0.15–0.62)< 0.001Placebo23/3467.6Reference–POUR was defined as failure to void within six hours postoperatively with a post-void bladder volume > 400 mL, requiring catheterization. Relative risk is calculated using Placebo as reference. Table 2Incidence of postoperative urinary retention (POUR).Groupn/N%Relative Risk (95% CI)P-valueBTX7/3420.60.30 (0.15–0.62)< 0.001Placebo23/3467.6Reference–POUR was defined as failure to void within six hours postoperatively with a post-void bladder volume > 400 mL, requiring catheterization. Relative risk is calculated using Placebo as reference. Incidence of postoperative urinary retention (POUR). POUR was defined as failure to void within six hours postoperatively with a post-void bladder volume > 400 mL, requiring catheterization. Relative risk is calculated using Placebo as reference. Fig. 2Absolute risk reduction in postoperative urinary retention associated with botulinum toxin compared with placebo. Values represent risk differences with 95% confidence intervals. Absolute risk reduction in postoperative urinary retention associated with botulinum toxin compared with placebo. Values represent risk differences with 95% confidence intervals. Multivariable logistic regression adjusting for age, sex, and opioid consumption demonstrated that placebo treatment was independently associated with a significantly higher likelihood of POUR (adjusted OR 8.87; 95% CI 2.82–27.95; P < 0.001; Table 3; Fig. 3). Age and sex were not significant predictors (P = 0.91 and P = 0.40, respectively), whereas higher postoperative opioid consumption was associated with increased odds of retention (adjusted OR 1.15; 95% CI 1.02–1.30; P = 0.02). Adjusted predicted probabilities from the regression model further illustrated the strength of the treatment effect, with a predicted probability of 20% (95% CI 7–33%) in the BTX group versus 68% (95% CI 53–84%) in the placebo group (Fig. 4). Sex-stratified analyses confirmed a consistent reduction in POUR among both male and female patients receiving BTX, with no significant treatment-by-sex interaction (Fig. 5). Table 3Multivariable logistic regression for predictors of POUR.VariableAdjusted OR95% CIP-valueTreatment (Placebo vs. BTX)8.872.82–27.95< 0.001Age1.010.96–1.050.91Sex (Male vs. Female)1.620.53–4.950.40Opioid consumption (mg, POD1)1.151.02–1.300.02Adjusted odds ratios (OR) were derived from a logistic regression model including treatment group, age, sex, and opioid consumption (mg morphine equivalents, POD1). Table 3Multivariable logistic regression for predictors of POUR.VariableAdjusted OR95% CIP-valueTreatment (Placebo vs. BTX)8.872.82–27.95< 0.001Age1.010.96–1.050.91Sex (Male vs. Female)1.620.53–4.950.40Opioid consumption (mg, POD1)1.151.02–1.300.02Adjusted odds ratios (OR) were derived from a logistic regression model including treatment group, age, sex, and opioid consumption (mg morphine equivalents, POD1). Multivariable logistic regression for predictors of POUR. Adjusted odds ratios (OR) were derived from a logistic regression model including treatment group, age, sex, and opioid consumption (mg morphine equivalents, POD1). Fig. 3Forest plot of adjusted odds ratios for postoperative urinary retention derived from multivariable logistic regression. Odds ratios are shown with 95% confidence intervals; the vertical line indicates no effect (OR = 1). Forest plot of adjusted odds ratios for postoperative urinary retention derived from multivariable logistic regression. Odds ratios are shown with 95% confidence intervals; the vertical line indicates no effect (OR = 1). Fig. 4Adjusted predicted probability of postoperative urinary retention by treatment group, estimated from a logistic regression model adjusted for age and sex. Error bars indicate 95% confidence intervals. Adjusted predicted probability of postoperative urinary retention by treatment group, estimated from a logistic regression model adjusted for age and sex. Error bars indicate 95% confidence intervals. Fig. 5Sex-stratified adjusted predicted probability of postoperative urinary retention by treatment group. Estimates were obtained from a logistic regression model including a treatment-by-sex interaction term. Sex-stratified adjusted predicted probability of postoperative urinary retention by treatment group. Estimates were obtained from a logistic regression model including a treatment-by-sex interaction term. Secondary outcomes indicated improved postoperative recovery in the BTX group. Median VAS pain scores were significantly lower at all measured time points (Day 1: 6.0 vs. 8.0; Week 2: 2.2 vs. 5.1; both P < 0.001). Correspondingly, cumulative NSAID consumption during the first postoperative day was reduced in the BTX group (34.5 ± 12.4 mg vs. 55.9 ± 15.8 mg; P < 0.001), and opioid requirements were lower (6.2 ± 3.1 vs. 10.4 ± 2.8 mg; P = 0.01; Table 4). Rates of transient gas incontinence and postoperative bleeding were low and comparable between groups, and no cases of anal stenosis were reported (Table 4). Table 4Secondary outcomes: pain scores and postoperative complications.VariableBTX group (n = 34)Placebo group (n = 34)P-valueVAS pain score (Day 1), median (IQR)6.0 (5–7)8.0 (7–9)< 0.001VAS pain score (Week 2), median (IQR)2.2 (1–3)5.1 (4–6)< 0.001Analgesic intake (NSAID mg, mean ± SD) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:34.5\pm\:12.4$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:55.9\pm\:15.8$$\end{document} < 0.001Opioid consumption (mg morphine equivalents, POD1)6.2 ± 3.110.4 ± 2.80.01Gas incontinence (Day 1), n (%)2 (5.9%)1 (2.9%)0.55Postoperative bleeding, n (%)1 (2.9%)2 (5.9%)0.55Anal stenosis, n (%)00–Pain intensity was measured using the Visual Analogue Scale (VAS, 0–10). Analgesic intake refers to cumulative NSAID consumption during the first postoperative day. Opioid consumption is reported as mg morphine equivalents, POD1. Table 4Secondary outcomes: pain scores and postoperative complications.VariableBTX group (n = 34)Placebo group (n = 34)P-valueVAS pain score (Day 1), median (IQR)6.0 (5–7)8.0 (7–9)< 0.001VAS pain score (Week 2), median (IQR)2.2 (1–3)5.1 (4–6)< 0.001Analgesic intake (NSAID mg, mean ± SD) \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:34.5\pm\:12.4$$\end{document} \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:55.9\pm\:15.8$$\end{document} < 0.001Opioid consumption (mg morphine equivalents, POD1)6.2 ± 3.110.4 ± 2.80.01Gas incontinence (Day 1), n (%)2 (5.9%)1 (2.9%)0.55Postoperative bleeding, n (%)1 (2.9%)2 (5.9%)0.55Anal stenosis, n (%)00–Pain intensity was measured using the Visual Analogue Scale (VAS, 0–10). Analgesic intake refers to cumulative NSAID consumption during the first postoperative day. Opioid consumption is reported as mg morphine equivalents, POD1. Secondary outcomes: pain scores and postoperative complications. Pain intensity was measured using the Visual Analogue Scale (VAS, 0–10). Analgesic intake refers to cumulative NSAID consumption during the first postoperative day. Opioid consumption is reported as mg morphine equivalents, POD1. Discussion The present trial demonstrates that intrasphincteric BTX injection profoundly reduces the incidence of POUR following stapled hemorrhoidopexy, with retention rates dropping from 67.6% in the placebo group to 20.6% in the intervention arm. Notably, the POUR rate observed in our control cohort exceeds the commonly cited historical range of 15% to 50%1,4,18. This discrepancy, rather than representing an anomaly, underscores the high diagnostic sensitivity of our specific methodology. Our study defined POUR using a strict 6-hour temporal threshold coupled with objective sonographic confirmation (post-void residual > 400 mL). Urodynamic and pharmacodynamic literature indicates that sacral parasympathetic blockade, which governs detrusor contraction, persistently outlasts both somatic motor and sensory recovery following spinal anesthesia10. Consequently, assessments conducted at 6 h capture a significant proportion of transient, anesthesia-induced retention that might resolve spontaneously and go undocumented in studies utilizing longer observation windows of 12 to 24 h or relying solely on subjective patient complaints16,17. Furthermore, the adjunctive use of intrathecal fentanyl in our cohort is a well-established independent risk factor that powerfully suppresses the micturition reflex arc, inevitably elevating baseline retention rates10,16. While historical prevention strategies have largely concentrated on fluid restriction and optimizing analgesia5,19, our findings robustly support the hypothesis that POUR is deeply rooted in complex neuromuscular dysregulation. Reduced nociceptive input from stapled hemorrhoidopexy (compared to conventional excisional surgery) does not entirely abrogate POUR, because pain-induced sympathetic activation is only one facet of the etiology1,20. The external anal sphincter, puborectalis, and urethral sphincter complex are functionally intertwined21. Iatrogenic stimulation and transient hypertonia of the pelvic floor muscles create an environment of dyssynergia, augmenting urethral outflow resistance while the detrusor remains pharmacologically depressed. The efficacy of intrasphincteric BTX injection, which cleaves SNARE proteins and inhibits acetylcholine release at motor nerve terminals, suggests that therapeutic success relies on direct neuromuscular modulation22,23. Although BTX recipients in our study consistently reported lower VAS scores and required fewer analgesics, the magnitude of POUR reduction (absolute risk reduction of 47%) indicates that the toxin mechanically disrupts the pathological reflex loop. By directly inducing temporary relaxation of the internal anal sphincter, BTX neutralizes the propagation of hypertonicity across the contiguous pelvic musculature, fundamentally restoring the critical balance between detrusor contraction and urethral sphincter relaxation20,24. From a perioperative management perspective, the integration of BTX represents a paradigm shift from reactive symptom management through measures such as catheterization to targeted prophylactic modulation of the underlying neuroanatomy. While the intervention effectively curtailed opioid and NSAID consumption without increasing short-term risks such as flatus incontinence or bleeding, the clinical utility of this approach must be weighed against the cost of the toxin. This study is not without limitations. Foremost is the absence of objective baseline and postoperative physiological metrics, such as urodynamic studies or anorectal manometry, which precludes a definitive, quantitative mapping of the sphincteric tone reduction. Additionally, the utilization of a standardized, arbitrary 50-unit dose leaves the optimal dose-response relationship uncharacterized. Although the sample size was adequate to detect the observed difference in POUR incidence, it was not determined through a formal power calculation specifically based on urinary retention rates. Therefore, the study may have been underpowered to detect smaller between-group differences. Nevertheless, the substantial effect size observed in this trial supports the robustness and clinical relevance of the findings. Future prospective trials should integrate objective pressure assessments to definitively separate the direct mechanical effects of BTX from its secondary analgesic benefits. Moreover, enriched trial designs investigating dose titration, alternative injection timings, and stratification by preoperative pelvic floor functionality, including baseline constipation severity, will be crucial for establishing BTX as a cost effective, standard of care adjunct in enhanced recovery after surgery ERAS pathways for anorectal procedures. Conclusion In sum, the present analysis supports the notion that postoperative urinary retention after stapled hemorrhoidopexy is not merely a byproduct of surgical pain and anesthesia, but a manifestation of broader neuromuscular dysregulation within pelvic floor networks. Intrasphincteric botulinum toxin injection appears to mitigate this complication by modulating muscle tone and potentially restoring more physiologic coordination between anal sphincter relaxation and bladder emptying reflexes. These data expand the conceptual framework for POUR prevention and suggest that targeted perioperative neuromuscular modulation may offer a meaningful adjunct to traditional analgesic and fluid management strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2